Summary
Thermo Fisher Scientific Inc. (TMO) reported first-quarter 2006 results with a notable 22% increase in revenue to $684.3 million, driven significantly by acquisitions, which contributed 17% to revenue growth. While overall revenue saw a 10% organic increase excluding acquisitions and currency impacts, the company's operating income margin slightly decreased to 9.9% from 10.7% in the prior year. This margin compression is primarily attributed to higher amortization expenses related to recent acquisitions and increased restructuring costs. Despite the margin pressure, the company demonstrated solid operational cash flow of $31.9 million. Management expressed confidence in the company's liquidity, citing sufficient existing cash, investments, and credit facilities to meet anticipated capital requirements for at least the next 24 months. The company is actively managing restructuring efforts, including plant consolidations, with ongoing evaluations for further cost-saving measures.
Key Highlights
- 1Revenue increased by 22% year-over-year to $684.3 million, with acquisitions contributing significantly to growth.
- 2Operating income grew to $67.8 million, but the operating income margin declined to 9.9% from 10.7% due to higher amortization and restructuring costs.
- 3Net income from continuing operations slightly decreased to $43.6 million from $45.6 million, impacted by higher interest expenses and an increased effective tax rate.
- 4Cash flow from operating activities remained strong at $31.9 million.
- 5The company adopted SFAS No. 123R, which requires the expensing of stock-based compensation, resulting in a $5.3 million pre-tax expense for the quarter.
- 6The company is actively managing restructuring initiatives, including a planned plant closure and consolidation, with expected charges of approximately $8 million in Q2 and Q3 2006.
- 7Management anticipates that existing resources and credit facilities are sufficient to meet capital requirements for the foreseeable future (at least 24 months).